التفاصيل البيبلوغرافية
| العنوان: |
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes |
| المؤلفون: |
Anne-Marie Ruppert, MD, PhD, Michèle Beau-Faller, MD, PhD, Didier Debieuvre, MD, L’Houcine Ouafik, MD, PhD, Virginie Westeel, MD PhD, Isabelle Rouquette, MD, Julien Mazières, MD, PhD, Pierre-Paul Bringuier, MD, Isabelle Monnet, MD, Fabienne Escande, MD, Charles Ricordel, MD, Jean-Philippe Merlio, MD, PDh, Henri Janicot, MD, Antoinette Lemoine, MD, PhD, Pascal Foucher, MD, Michel Poudenx, MD, Franck Morin, MSc, Alexandra Langlais, MSc, Pierre-Jean Souquet, MD, PhD, Fabrice Barlesi, MD, PhD, Marie Wislez, MD, PhD |
| المصدر: |
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100052- (2020) |
| بيانات النشر: |
Elsevier, 2020. |
| سنة النشر: |
2020 |
| المجموعة: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: |
KRAS mutation, Non–small cell lung cancer, NSCLC, Prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: |
Introduction: KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods: In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the KRAS mutations subtype. Results: Over 95% of patients with KRAS mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma (82.5%). The most common KRAS mutation subtype was G12C (374 patients; 41.5%), followed by G12V (168; 18.6%), G12D (131; 14.5%), G12A (62; 6.9%), G13C (45; 5.0%), G13D (31; 3.4%), and others (10; 1%). Approximately 21% of patients had transition mutation and 68.2% had a transversion mutation. G12D and transition mutations were predominant in never-smokers. The median overall survival for patients with KRAS-mutated NSCLC was 8.1 months (95% confidence interval [CI]: 7.5–9.5), without any differences according to the different KRAS subtypes mutations. The median progression-free survival was 4.6 months (95% CI: 4.2–5.1) for first-line treatment and 4.8 months (95% CI: 4.3–6.8) for second-line treatment, without any differences according to the different KRAS subtypes mutations. Conclusions: KRAS mutation subtypes influenced neither treatment responses nor outcomes. The KRAS G12C mutation was detected in 41.5% of patients, who are now eligible for potent and specific G12C inhibitors. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2666-3643 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S2666364320300576; https://doaj.org/toc/2666-3643 |
| DOI: |
10.1016/j.jtocrr.2020.100052 |
| URL الوصول: |
https://doaj.org/article/0738da11c0534bb49bbf4eba273784d4 |
| رقم الانضمام: |
edsdoj.0738da11c0534bb49bbf4eba273784d4 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder